<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00666341</url>
  </required_header>
  <id_info>
    <org_study_id>AL0701rP</org_study_id>
    <secondary_id>2007-002808-18</secondary_id>
    <nct_id>NCT00666341</nct_id>
  </id_info>
  <brief_title>Dose-Response-Study With a Recombinant Cocktail of Phleum (rPhleum) Allergens</brief_title>
  <official_title>A Double-blind Placebo-controlled Dose-response Study for Evaluation of Safety and Efficacy of Immunotherapy With a Cocktail of Recombinant Major Allergens of Timothy Grass Pollen (Phleum Pratense) Adsorbed to Aluminium Hydroxide in Patients With IgE-mediated Allergic Rhinitis/Rhinoconjunctivitis With or Without Bronchial Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergopharma GmbH &amp; Co. KG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergopharma GmbH &amp; Co. KG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dose-response trial with a cocktail of recombinant major allergens of Timothy Grass Pollen
      (Phleum pratense)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systemic reaction (according to Tryba)</measure>
    <time_frame>uptitration phase</time_frame>
    <description>Number of patients with at least one systemic reaction (according to Tryba Grade 1-4) with possible, probable or definite relationship to the study medication determined at the end of the uptitration phase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Late Phase Reactions</measure>
    <time_frame>before and at the end of the double-blind phase</time_frame>
    <description>Changes of the Late Phase Reactions in specific intracutaneous test with natural allergen before and at the end of the double-blind placebo controlled phase before grass pollen season.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Type I-Allergy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: Al(OH)3-Placebos with histamine-dihydrochloride analogue Allergen-Adsorbate rPhleum strengthes 1 to 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 μg rPhleum Immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 1 (20 μg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40 μg rPhleum Immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 2 (40 μg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>80 μg rPhleum Immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 3 (80 μg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>120 μg rPhleum Immunotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 4 (120 μg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo: Al(OH)3-Placebos with histamine-dihydrochloride analogue Allergen-Adsorbate rPhleum strengthes 1 to 4.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rPhleum</intervention_name>
    <description>Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 1 (20 μg)</description>
    <arm_group_label>20 μg rPhleum Immunotherapy</arm_group_label>
    <other_name>Specific Immunotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rPhleum</intervention_name>
    <description>Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 2 (40 μg)</description>
    <arm_group_label>40 μg rPhleum Immunotherapy</arm_group_label>
    <other_name>Specific Immunotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rPhleum</intervention_name>
    <description>Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 3 (80 μg)</description>
    <arm_group_label>80 μg rPhleum Immunotherapy</arm_group_label>
    <other_name>Specific Immunotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rPhleum</intervention_name>
    <description>Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 4 (120 μg)</description>
    <arm_group_label>120 μg rPhleum Immunotherapy</arm_group_label>
    <other_name>Specific Immunotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  main symptoms of allergic rhinitis/rhinoconjunctivitis with or without controlled
             asthma against grass pollen allergens

          -  positive SPT

          -  positive EAST

          -  positive specific provocation test

        Exclusion Criteria:

          -  serious chronic diseases

          -  other perennial allergies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karl Hörmann, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitätsklinikum Mannheim GMBH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prof. Dr. med. Ludger Klimek</name>
      <address>
        <city>Wiesbaden</city>
        <state>Baden-W.</state>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.allergopharma.de</url>
    <description>Leader in specific allergy research and therapy</description>
  </link>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-002808-18/DE</url>
    <description>Click here for information about this trial in the European Clinical Trials Register</description>
  </link>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2008</study_first_submitted>
  <study_first_submitted_qc>April 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2008</study_first_posted>
  <last_update_submitted>November 7, 2013</last_update_submitted>
  <last_update_submitted_qc>November 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Histamine</mesh_term>
    <mesh_term>Histamine phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

